NOW ENROLLING

ENHANCE-3: A study for individuals with untreated AML ineligible for intensive chemotherapy

ENHANCE-3 is a clinical research study investigating magrolimab plus venetoclax and azacitidine versus placebo plus venetoclax and azacitidine in adults with previously untreated AML who are not eligible for intensive chemotherapy.

Selected Eligibility Criteria

- 18 years of age or older
- Previously untreated AML and ineligible for treatment with a standard cytarabine and anthracycline induction regimen
- No prior treatment with CD47- or SIRPα-targeting agent or with antileukemic therapy (excluding hydroxyurea)

If you are interested in participating in ENHANCE-3 and meet these criteria, please ask your doctor about your eligibility and further details about the study.

Visit ClinicalTrials.gov and search NCT05079230 for more information. The safety, efficacy and uses of magrolimab have not been established. There is no guarantee that magrolimab will be approved by the FDA or other global health authorities in AML.

Trial Schematic

Trial Population
Newly diagnosed, previously untreated patients with AML who are ineligible for treatment with a standard cytarabine and anthracycline induction regimen

1:1 Randomization

Magrolimab + Venetoclax + Azacitidine (N=216)

Placebo + Venetoclax + Azacitidine (N=216)

AML, acute myeloid leukemia; CD, cluster of differentiation; SIRPα, signal regulatory protein alpha.

GILEAD and the GILEAD Logo are trademarks of Gilead Sciences, Inc. 333 Lakeside Drive, Foster City, CA 94404 © 2022 Gilead Sciences, Inc. All rights reserved.